Fasenra vs. Xolair

• Are Fasenra and Xolair the Same Thing?
• What Are Possible Side Effects of Fasenra?
• What Are Possible Side Effects of Xolair?
• What Is Fasenra?
• What Is Xolair?
• What Drugs Interact with Fasenra?
• What Drugs Interact with Xolair?
• How Should Fasenra Be Taken?
• How Should Xolair Be Taken?

Fasenra (benralizumab) and Xolair (omalizumab) are IgG1? monoclonal antibodies used to treat severe asthma in patients aged 12 years and older.

Xolair is usually given after other asthma medications have been tried without successful treatment of symptoms.

Xolair is also used to treat adults and adolescents 12 years of age and older with chronic idiopathic hives (urticaria) who remain symptomatic despite H1 antihistamine treatment.

Side effects of Fasenra and Xolair that are similar include headache, sore throat, and injection site reactions (itching, redness, stinging, pain, bruising, warmth, burning, or swelling).

Side effects of Fasenra that are different from Xolair include fever and hypersensitivity reactions.

Side effects of Xolair that are different from Fasenra include tired feeling, joint or muscle pain, dizziness, ear pain, hair loss, cold symptoms, itching or skin rash, and leg or arm pain.

Both Fasenra and Xolair may interact with other drugs.

Common side effects of Fasenra include:

• headache,
• sore throat,
• fever,
• hypersensitivity reactions, and
• injection site reactions (pain, redness, itching, or a small lump)

Common side effects of Xolair include:

• headache,
• tired feeling,
• joint or muscle pain,
• dizziness,
• ear pain,
• hair loss,
• sore throat,
• cold symptoms,
• itching or skin rash,
• injection site reactions (itching, redness, stinging, pain, bruising, warmth, burning, or swelling), or
• leg or arm pain.

Tell your doctor if you have serious side effects of Xolair including unusual lumps/growths/moles.

Fasenra (benralizumab) injection is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Xolair (omalizumab) is an antibody that helps decrease allergic responses in the body used to treat moderate to severe asthma that is caused by allergies in adults and children who are at least 12 years old. Xolair is usually given after other asthma medications have been tried without successful treatment of symptoms.

Fasenra may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Fasenra; it is unknown how it would affect a fetus. Monoclonal antibodies such as Fasenra are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy. It is unknown if Fasenra passes into breast milk or how it would affect a nursing infant. Consult your doctor before breastfeeding.

Before using Xolair, tell your doctor if you are receiving allergy shots. There may be other drugs that can interact with Xolair. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor. Xolair should be used only when prescribed during pregnancy. It is not known whether this drug passes into breast milk. Consult your doctor before breastfeeding.

• Are Fasenra and Xolair the Same Thing?
• What Are Possible Side Effects of Fasenra?
• What Are Possible Side Effects of Xolair?
• What Is Fasenra?
• What Is Xolair?
• What Drugs Interact with Fasenra?
• What Drugs Interact with Xolair?
• How Should Fasenra Be Taken?
• How Should Xolair Be Taken?

Fasenra (benralizumab) injection and Xolair Diskus (fluticasone and salmeterol oral inhaler) are used to treat asthma.

Xolair Diskus is also used to treat chronic bronchitis, including COPD associated with chronic bronchitis. Xolair Diskus is used in patients whose symptoms are not adequately controlled on a long-term asthma control medication, since one of the active ingredients in salmeterol is LABA, which has been linked to asthma-related deaths. Xolair Diskus should not be used to treat acute episodes of asthma or COPD.

Fasenra and Xolair Diskus belong to different drug classes. Fasenra is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) and Xolair Diskus is a combination of a corticosteroid and a beta2-adrenergic bronchodilator.

Side effects of Fasenra and Xolair Diskus that are similar include headache and sore throat.

Side effects of Fasenra that are different from Xolair Diskus include fever, hypersensitivity reactions, and injection site reactions (pain, redness, itching, or a small lump).

Side effects of Xolair Diskus that are different from Fasenra include upper respiratory tract infections, dizziness, nausea, vomiting, stomach upset, diarrhea, yeast infections of the mouth or throat (oral thrush), dry mouth/nose/throat, stuffy nose, sinus pain, cough, sore throat, hoarseness or deepened voice, and musculoskeletal pain.

Fasenra may interact with other drugs.

Xolair Diskus may interact with amiodarone, diuretics (water pills), HIV medicines, MAO inhibitors, antidepressants, antibiotics, antifungal medications, and beta-blockers.

Common side effects of Fasenra include:

• headache,
• sore throat,
• fever,
• hypersensitivity reactions, and
• injection site reactions (pain, redness, itching, or a small lump)

Common side effects of Xolair include:

• nausea,
• vomiting,
• stomach pain,
• diarrhea,
• headache,
• dizziness,
• depression,
• joint pain,
• trouble sleeping,
• strange dreams,
• back pain,
• itching or skin rash,
• changes in the color of skin on your palms or soles of your feet, or
• changes in the shape or location of body fat (especially in your arms, legs, face, neck, breasts, and waist).

Tell your doctor if you have serious side effects of Xolair including:

• mental/mood changes (such as depression, anxiety),
• loss of appetite,
• stomach or abdominal pain,
• pink or bloody urine, or
• changes in the amount of urine.

Fasenra (benralizumab) injection is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Xolair (emtricitabine/tenofovir disoproxil fumarate) is a combination of antiviral drugs used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). Xolair is not a cure for HIV or AIDS.

Fasenra may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Fasenra; it is unknown how it would affect a fetus. Monoclonal antibodies such as Fasenra are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy. It is unknown if Fasenra passes into breast milk or how it would affect a nursing infant. Consult your doctor before breastfeeding.

Xolair may interact with lithium, methotrexate, pain or arthritis medicines, medicines used to prevent organ transplant rejection, IV antibiotics, antiviral medicines, cancer medicines, herpes medications, medications to treat cytomegalovirus (CMV), or other HIV medicines. Tell your doctor all medications and supplements you use. During pregnancy, Xolair should be used only when prescribed. It is normal to prescribe HIV medicines such as Xolair for pregnant women with HIV. This can decrease the risk of passing HIV to the baby. Xolair may be part of that treatment. Consult your doctor. It is unknown if Xolair passes into breast milk. Because breast milk can transmit HIV, do not breastfeed.

The dose of Fasenra is one tablet taken orally once daily with or without food.

Xolair in a dose of 150 to 375 mg is administered by injection every 2 or 4 weeks.